Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$9310.00
-10.00 (-0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.2B · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$87.1B
P/E
14.2x
↓EV/EBITDA
6.4x
↓ROE
5.8%
↑Gross Margin
48.7%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.7%
FCF CAGR
—
FCF margin
3.9%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $49.07B · net income $6.16B · FCF $1.90B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $49.07B | $49.07B | $45.59B | $41.87B | $39.30B |
| Net Income | $6.16B | $6.16B | $6.85B | $6.00B | $4.04B |
| EBITDA | $13.09B | $13.09B | $13.69B | $13.34B | $11.10B |
| EPS | 656.00 | 656.00 | 713.00 | 621.00 | 415.00 |
| Gross Margin | 48.7% | 48.7% | 46.7% | 51.4% | 47.8% |
| Operating Margin | 13.2% | 13.2% | 12.6% | 16.7% | 10.9% |
| Net Margin | 12.5% | 12.5% | 15.0% | 14.3% | 10.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.09 | 0.11 | 0.13 |
| Current Ratio | 3.11 | 3.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.90B | $1.90B | $6.23B | $10.79B | $-83.8M |
| Returns | |||||
| ROE | 5.8% | 5.8% | 6.6% | 6.0% | 4.2% |
| Valuation | |||||
| P/E | 14.19 | 14.19 | 13.87 | 17.29 | 26.02 |
| EV/EBITDA | 6.41 | 6.41 | 6.61 | 7.53 | 9.90 |
| P/B | 0.83 | 0.83 | 0.91 | 1.04 | 1.10 |
| Growth & Yield | |||||
| Revenue Growth | 7.6% | 7.6% | 8.9% | 6.5% | — |
| EPS Growth | -8.0% | -8.0% | 14.8% | 49.6% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.0%
EPS terminal req.
$826.11
Spread vs growth
-16.0%
5Y implied EPS CAGR
8.8%
EPS terminal req.
$999.59
Spread vs growth
-16.8%
10Y implied EPS CAGR
9.4%
EPS terminal req.
$1609.85
Spread vs growth
-17.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.0%
Start / end P/E
13.8x → 14.2x
EPS bridge
713.00 → 656.00
Residual
-0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.